June 15, 2026: Sudarshan Pharma has announced the allotment of 90 lakh equity shares following the conversion of 9 lakh warrants held by promoter group entities. The allotment was approved by the company’s Warrants Committee on June 12, 2026.
Author: Aadarsh Patel | EQMint
The shares have been issued at an adjusted price of ₹16.983 per share, resulting from the company’s earlier stock subdivision. Following the conversion, the company received ₹11.46 crore as the balance amount payable on the warrants.
Promoters Increase Holding
The newly allotted shares were issued to promoter entities:
- Hemal Vasantrai Mehta – 45 lakh shares
- Sachin Vasantrai Mehta – 45 lakh shares
Together, the conversion resulted in the allotment of 90 lakh equity shares.
Share Capital Increases
Following the allotment, Sudarshan Pharma’s paid-up equity capital has increased to 24.96 crore shares, with promoter and promoter group shareholding rising to 58.93%, while public shareholding stands at 41.07%.
EQMint Analysis on Sudarshan Pharma
The conversion of warrants by promoters is generally viewed as a positive signal because it indicates continued confidence in the company’s future prospects. By infusing additional capital and increasing ownership, promoters are effectively strengthening their commitment to the business.
While warrant conversions increase the number of outstanding shares, investors often focus on the message behind the move. In this case, the increased promoter stake could be interpreted as management’s confidence in Sudarshan Pharma’s growth plans, particularly as the company continues to expand its pharmaceutical and healthcare operations.
For more such information visit EQMint
Join our Whatsapp channel for timely updates: Whatsapp
Disclaimer: This article is not an investment advice and is for educational purpose only.
